# EDGAR Filing Document

**Accession Number:** 0000315545
**File Stem:** 0001493152-26-004730
**Filing Date:** 2026-2
**Character Count:** 13391
**Document Hash:** c31f2ba9f65c0a3aea19f6072e7868d3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-004730.hdr.sgml**: 20260202

**ACCESSION NUMBER**: 0001493152-26-004730

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260130

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260202

**DATE AS OF CHANGE**: 20260202

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PROVECTUS BIOPHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0000315545
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 900031917
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36457
- **FILM NUMBER:** 26587519

**BUSINESS ADDRESS:**
- **STREET 1:** 800 S. GAY STREET
- **STREET 2:** SUITE 1610
- **CITY:** KNOXVILLE
- **STATE:** TN
- **ZIP:** 37929
- **BUSINESS PHONE:** (866) 594-5999

**MAIL ADDRESS:**
- **STREET 1:** 800 S. GAY STREET
- **STREET 2:** SUITE 1610
- **CITY:** KNOXVILLE
- **STATE:** TN
- **ZIP:** 37929

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PROVECTUS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20020417

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZAMAGE DIGITAL IMAGING INC
- **DATE OF NAME CHANGE:** 20011126

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SPM GROUP INC
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 30, 2026**

**PROVECTUS BIOPHARMACEUTICALS, INC.**

(Exact name of registrant as specified in charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36457** | **90-0031917** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

**800 S. Gay Street, Suite 1610, Knoxville, TN 37929**

(Address of Principal Executive Offices) (Zip Code)

**(866) 594-5999**

(Registrant's Telephone Number, Including Area Code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **None** | **N/A** | **N/A** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.**

On January 30, 2026, Provectus Biopharmaceuticals, Inc. (the "Company") filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock (the "Series D Amendment") and a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock (the "Series D-1 Amendment," and together with the Series D Amendment, the "Amendments") with the Secretary of State of the State of Delaware.

The Amendments were approved by the Company's board of directors and a special committee comprised entirely of independent directors.

The Amendments extend the date on which shares of the Company's Series D Convertible Preferred Stock, par value $0.001 per share, and shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share, will automatically convert into shares of the Company's common stock, par value $0.001 per share (the "Automatic Conversion Date"). The prior Automatic Conversion Date was June 20, 2026. Following the Amendments, the Automatic Conversion Date is December 31, 2028.

The foregoing descriptions of the Series D Amendment and Series D-1 Amendment do not purport to be complete and are qualified in their entirety by reference to the full text of the Amendments, copies of which are filed as Exhibits 3.1 and 3.2, respectively, to this Current Report and are incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| Exhibit<br> Number | Description |
| 3.1 | [Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock](ex3-1.htm) |
| 3.2 | [Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock](ex3-2.htm) |
| 104 | Cover Page Interactive Date File (the cover page XBRL tags are embedded within the inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 2, 2026

---

| | |
|:---|:---|
| **PROVECTUS BIOPHARMACEUTICALS, INC.** | **PROVECTUS BIOPHARMACEUTICALS, INC.** |
| By: | */s/ Heather Raines* |
|  | Heather Raines |
|  | Chief Financial Officer (Principal Financial Officer) |

---

## Exhibit 3.1

**Exhibit 3.1**

**CERTIFICATE OF AMENDMENT**

**TO**

**CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS**

**OF**

**SERIES D CONVERTIBLE PREFERRED STOCK**

**OF**

**PROVECTUS BIOPHARMACEUTICALS, INC.**

**PURSUANT TO SECTION 151 OF THE**

**DELAWARE GENERAL CORPORATION LAW**

Provectus Biopharmaceuticals, Inc. (the "<u>Company</u>"), a corporation organized and existing and by virtue of the General Corporation Law of the State of Delaware ("<u>DGCL</u>"), does hereby certify:

FIRST: The Company's Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock was filed with the Secretary of State of the State of Delaware on June 17, 2021 and was subsequently amended by that certain Certificate of Amendment, dated June 24, 2024 (as amended, the "<u>Certificate of Designation</u>").

SECOND: The Board of Directors of the Company, acting by unanimous written consent pursuant to Section 141 of the DGCL, duly adopted resolutions extending the date on which shares of Series D Convertible Preferred Stock, par value $0.001 per share (the "<u>Series D Convertible Preferred Stock</u>") will automatically convert into shares of common stock, par value $0.001 per share, and approving the form of this amendment to the Certificate of Designation set forth below:

RESOLVED, that the Certificate of Designation is hereby amended by deleting Section 8 in its entirety and replacing it with the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Automatic Conversion</u>. On December 31, 2028, all of the outstanding shares of Series D Convertible Preferred Stock held by stockholders shall automatically convert into an equal number of Conversion Shares without any further action by the relevant holder of such shares or the Corporation. All Conversion Shares issued hereunder by the Corporation shall be duly and validly issued, fully paid and nonassessable, free and clear of all taxes, liens, charges and encumbrances with respect to the issuance thereof. As promptly as practicable following December 31, 2028 (but in any event within ten Business Days thereafter), the Corporation shall send each holder of shares of Series D Convertible Preferred Stock written notice of such event. Upon receipt of such notice, each holder shall surrender to the Corporation the certificate or certificates representing the shares being converted, duly assigned or endorsed for transfer to the Corporation (or accompanied by duly executed stock powers relating thereto) or, in the event the certificate or certificates are lost, stolen or missing, accompanied by an affidavit of loss executed by the holder. Upon the surrender of such certificate(s) and accompanying materials, the Corporation shall as promptly as practicable (but in any event within ten (10) Business Days thereafter) deliver to the relevant holder a certificate in such holder's name (or the name of such holder's designee as stated in the written election) for the number of Conversion Shares to which such holder shall be entitled upon conversion of the applicable shares.

IN WITNESS WHEREOF, the undersigned has executed this Certificate of Amendment as of the 30<sup>th</sup> day of January, 2026.

---

| | |
|:---|:---|
| **PROVECTUS BIOPHARMACEUTICALS, INC.** | **PROVECTUS BIOPHARMACEUTICALS, INC.** |
| By: | */s/ Heather Raines* |
|  | Heather Raines |
|  | Chief Financial Officer |

---

## Exhibit 3.2

**Exhibit 3.2**

**CERTIFICATE OF AMENDMENT**

**TO**

**CERTIFICATE OF DESIGNATION OF PREFERENCES,** 

**RIGHTS AND LIMITATIONS**

**OF**

**SERIES D-1 CONVERTIBLE PREFERRED STOCK**

**OF**

**PROVECTUS BIOPHARMACEUTICALS, INC.**

**PURSUANT TO SECTION 151 OF THE** 

**DELAWARE GENERAL CORPORATION LAW**

Provectus Biopharmaceuticals, Inc. (the "<u>Company</u>"), a corporation organized and existing and by virtue of the General Corporation Law of the State of Delaware ("<u>DGCL</u>"), does hereby certify:

FIRST: The Company's Certificate of Designation of Preferences, Rights and Limitations of Series D-1 Convertible Preferred Stock was filed with the Secretary of State of the State of Delaware on June 17, 2021 and was subsequently amended by that certain Certificate of Amendment, dated March 30, 2022 and that certain Certificate of Amendment, dated June 24, 2024 (as amended, the "<u>Certificate of Designation</u>").

SECOND: The Board of Directors of the Company, acting by unanimous written consent pursuant to Section 141 of the DGCL, duly adopted resolutions extending the date on which shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share (the "<u>Series D-1 Convertible Preferred Stock</u>") will automatically convert into shares of common stock, par value $0.001 per share, and approving the form of this amendment to the Certificate of Designation set forth below:

RESOLVED, that the Certificate of Designation is hereby amended by deleting Section 8 in its entirety and replacing it with the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Automatic Conversion</u>. On December 31, 2028, each outstanding share of Series D-1 Convertible Preferred Stock held by stockholders shall automatically convert into ten Conversion Shares without any further action by the relevant holder of such shares or the Corporation. All Conversion Shares issued hereunder by the Corporation shall be duly and validly issued, fully paid and nonassessable, free and clear of all taxes, liens, charges and encumbrances with respect to the issuance thereof. As promptly as practicable following December 31, 2028 (but in any event within ten Business Days thereafter), the Corporation shall send each holder of shares of Series D-1 Convertible Preferred Stock written notice of such event. Upon receipt of such notice, each holder shall surrender to the Corporation the certificate or certificates representing the shares being converted, duly assigned or endorsed for transfer to the Corporation (or accompanied by duly executed stock powers relating thereto) or, in the event the certificate or certificates are lost, stolen or missing, accompanied by an affidavit of loss executed by the holder. Upon the surrender of such certificate(s) and accompanying materials, the Corporation shall as promptly as practicable (but in any event within ten (10) Business Days thereafter) deliver to the relevant holder a certificate in such holder's name (or the name of such holder's designee as stated in the written election) for the number of Conversion Shares to which such holder shall be entitled upon conversion of the applicable shares.

IN WITNESS WHEREOF, the undersigned has executed this Certificate of Amendment as of the 30<sup>th</sup> day of January, 2026.

---

| | |
|:---|:---|
| **PROVECTUS BIOPHARMACEUTICALS, INC.** | **PROVECTUS BIOPHARMACEUTICALS, INC.** |
| By: | */s/ Heather Raines* |
|  | Heather Raines |
|  | Chief Financial Officer |

---